Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Abgenix reports positive preliminary results from phase II trial of GVHD treatment

Feb. 5, 1999

EMEA marketing approval for Triacelluvax

Feb. 4, 1999

New immunomodulator LK-423 possesses unique pharmacological properties

Feb. 3, 1999

Clinical trials for Japanese immunosuppressant begin in Europe

Feb. 3, 1999

Priority review status assigned to Rapamune immunosuppressive therapy

Feb. 3, 1999

New herpes vaccine from Cel-Sci proves effective in protecting mice

Feb. 1, 1999

OraVax, Peptide Therapeutics and Pasteur Merieux Connaught announce agreements

Feb. 1, 1999

Antex Biologics successfully completes phase I study of Helicobacter vaccine

Jan. 29, 1999

Yoshitomi's new immunosuppressive agents for arthritis, autoimmune diseases and transplant rejection

Jan. 27, 1999

Another significant market introduction for basiliximab

Jan. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...